Entries by Philip Rye

AlgiPharma secures 22 MNOK in non-dilutive funding for development of its antimicrobial alginate oligosaccharide technology, with the goal to enhance fighting multidrug resistance.

December 20, 2021 in , /by

AlgiPharma has been awarded up to NOK 16 million from the Norwegian Research Councils Innovation Project for the Industrial Sector program for the project “Therapeutic Alginates for Resistant and Recurrent Infections: Generating Eradication Therapies (TARRGET)”. The project grant awarded from the Research Council combined with the Norwegian government tax incentive scheme (SkatteFUNN) results in a […]

AlgiPharma is Recruiting – Again!

May 14, 2020 in /by

Director Clinical Research / Chief Medical Officer AlgiPharma is interested to hear from high caliber, energetic candidates to join the team at our Norwegian office in Sandvika. The deadline for applications is the 24th May 2020 (see links below for further details). More details can be found at: – www.borka.no/jobb/director-clinical-research-chief-medical-officer/ – www.finn.no/177948590 – www.linkedin.com/groups/2085624 – […]

New parent company in the AlgiPharma group

January 22, 2020 in /by

AlgiPharma AS acquired by AlgiPharma AB On December 20, 2019 the Swedish AlgiPharma AB finalized the acquisition of the Norwegian AlgiPharma AS. All shareholders in AlgiPharma AS accepted the offer from AlgiPharma AB which means that the shareholders have the same number of shares and ownership percentage in the new parent company AlgiPharma AB as […]

AlgiPharma appoints new CFO

August 1, 2019 in /by

AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]

New 2b Clinical Trial started in Australia

April 30, 2019 in , /by

New Phase 2b Clinical Trial: A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205) A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th […]

AlgiPharma Appoints Director for Australian Operations

January 1, 2019 in /by

AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand. About Cystic Fibrosis: Cystic […]